Distinguished in Alpha-1 Antitrypsin Deficiency (AATD)

Jan N. Stolk

Leiden, ZH, NL 
Distinguished in Alpha-1 Antitrypsin Deficiency (AATD)
Leiden, ZH, NL 
OverviewLocationsClinical Research

Overview

Jan Stolk practices in Leiden, Netherlands. Stolk is rated as a Distinguished expert by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). Their top areas of expertise are Emphysema, Subcutaneous Emphysema, Alpha-1 Antitrypsin Deficiency (AATD), and Chronic Obstructive Pulmonary Disease (COPD).

Their clinical research consists of co-authoring 81 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 30 articles and participated in 1 clinical trial in the study of Alpha-1 Antitrypsin Deficiency (AATD).

Locations

Leiden, ZH, Netherlands
Other Locations
Zuideinde, OV, Netherlands
Ede, GE, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 1 Study to Determine the Safety, Tolerability, Pharmacokinetics and Effect of Circulating Alpha-1 Antitrypsin Levels of ARC-AAT in Healthy Volunteer Subjects and in Patients With Alpha-1 Antitrypsin Deficiency (AATD)
A Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 1 Study to Determine the Safety, Tolerability, Pharmacokinetics and Effect of Circulating Alpha-1 Antitrypsin Levels of ARC-AAT in Healthy Volunteer Subjects and in Patients With Alpha-1 Antitrypsin Deficiency (AATD)
Enrollment Status: Terminated
Publish Date: August 03, 2018
Intervention Type: Other, Drug
Study Phase: Phase 1

81 Total Publications

Performance of enhanced liver fibrosis test and indirect serum fibrosis markers for exclusion of advanced liver fibrosis in alpha-1 antitrypsin deficiency.
Performance of enhanced liver fibrosis test and indirect serum fibrosis markers for exclusion of advanced liver fibrosis in alpha-1 antitrypsin deficiency.
Journal: European journal of internal medicine
Published: April 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Stolk's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile